Healthcare | June 24, 2025
Biocon Biologics collaborates with National Cancer Society Malaysia
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
This strategic expansion marks a significant step in the company's global growth strategy
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Subscribe To Our Newsletter & Stay Updated
